News
Why sex and gender matter in Alzheimer’s research

An international panel of experts has issued a “consensus statement” on sex and gender disparities in resilience to Alzheimer’s disease; which they hope will help to shape future research.
Based on a review of a large body of literature, the panel identified sex and gender differences in dementia risk and identified a gap in the understanding of specific risk and resilience pathways.
While women tend to have an initial cognitive advantage, they decline faster than men as the disease progresses. This may be due to differential development of pathologies, known as resistance to Alzheimer’s disease, or different ability to maintain normal functioning over time and cope with pathology once this is present, known as cognitive resilience to Alzheimer’s disease.
In fact, women initially show greater resilience, coping better with brain pathology and atrophy and maintaining cognitive function. The greater initial resilience in women is supported by animal research showing a protective role of the X-Chromosome in Alzheimer’s disease (females typically have two X chromosomes, while males have one).
However, this initial resilience fades away as they progress towards a clinical diagnosis of mild cognitive impairment and Alzheimer’s disease, when they show greater vulnerability. Indeed, studies suggest that women are more likely to have an abnormal build-up of tau protein in the brain and show a higher burden of vascular pathologies, particularly after the menopause.
The authors propose various mechanisms explaining the difference in risk and resilience between women and men, including a higher prevalence of physical inactivity and affective disorders in women, but also biological factors. In this regard, genetic evidence suggests that resilience might be associated with immune pathways in females and cardiovascular pathways in men.
The panel was led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the “la Caixa” Foundation, under the umbrella of the Alzheimer’s Association International Society to Advance Alzheimer’s Research and Treatment. Its work has been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Eider Arenaza-Urquijo, first author of the study, said: “Assessing how sex and gender interact is crucial to understanding the mechanisms that maintain cognitive function and reduce the accumulation of pathologies in ageing and Alzheimer’s disease, i.e. resilience and resistance factors.”
According to the research team, studies of resilience in Alzheimer’s disease have mainly focused on individual behaviour, without taking into account how social and cultural factors, such as gender, influence behaviour and therefore risk and resilience. Importantly, differences in cognitive function between men and women may be decreasing as gender inequalities also decrease due to more opportunities for women in education, workforce participation, and improvements in their economic status and living conditions.
“Protective factors, such as education, may have different effects in men and women. We need to understand the complexity of interactions between biological and social factors to understand resilience to Alzheimer’s disease”, argues Arenaza-Urquijo.
For this reason, the authors call for a sex- and gender-sensitive approach to resilience to better understand the complex interplay of biological and social determinants. “Focusing more on the differential effects of modifiable factors will help to determine whether a particular factor has a greater impact on cognitive or brain resilience in men or women”, remarks Arenaza-Urquijo.
To improve our understanding of how sex and gender affect cognitive resilience to ageing and Alzheimer’s disease, the researchers recommend several directions for future studies. First, they stress the need to explore how sex and gender factors interact across cultures, taking into account the demographic, genetic, social and clinical differences that influence dementia risk.
They point out that sex/gender differences in brain characteristics, such as brain connectivity, remain understudied as resilience factors for Alzheimer’s disease that may minimise the impact of pathologies on cognition.
The authors also argue that publishing negative results is crucial to avoid bias and that all studies should include sex-disaggregated results.
Finally, they point out the importance of considering sex and gender in a non-binary way, and of including LGTBIQ+ populations, who are often underrepresented and face a higher burden of chronic disease.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








